Pharmacokinetic Study of Two Generic Co-formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF)
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This pilot pharmacokinetic study is designed to exclude a large difference (>40%) in
pharmacokinetics (esp. AUC) between two new Lopimune formulations and the branded
formulation. The formal bioequivalence study with adequate power will be conducted by the
manufacturer. In order to get data independently from the manufacturer and to have this
information in an earlier phase, this small pilot study is initiated.
The initial study showed a declined bioavailability of the granules under fasting conditions.
The study has been extended with an arm determining the pharmacokinetics of the granules
after food (compared to the oral solution taken with food).